The effect of BCG vaccine at birth on the development of atopy or allergic disease in young children

R. G. Townley, I. B. Barlan, C. Patino, P. Vichyanond, M. C. Minervini, T. Simasathien, R. Nettagul, N. N. Bahceciler, D. Basdemir, T. Akkoc, S. Pongprueksa, R. J. Hopp

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: Exposure to infectious diseases may reduce the development of asthma or allergy. In particular, the role of the BCG vaccine in modulating asthma or allergy has been a source of speculation. Objective: To study newborns from 3 international sites to evaluate the prospective effect of BCG vaccine on allergic diseases or atopic development. Methods: Infants were enrolled from newborn and well-infant clinics in Thailand, Argentina, and Turkey. The standard BCG vaccine for each country was given at birth. Parents who consented to have their infant included in the protocol completed an allergy family questionnaire. Infants underwent a standard purified protein derivative (PPD) test at 9 to 12 months of age, and the reaction size was measured. At the age of 2 years, the children returned to be studied. Allergy skin tests to common allergens appropriate to location and age were performed, and the parents completed the International Study of Allergy and Asthma in Childhood questionnaire. The PPD reaction size was compared with the presence of atopy and allergy questionnaire responses. Results: A total of 1,704 infants were studied. Statistical significance was found between a negative PPD response vs any positive PPD response and the risk of having an allergic history at the age of 2 years in Turkey (relative risk, 2.11; 95% confidence interval, 1.25-3.55; P = .005) and Thailand (relative risk, 2.16; 95% confidence interval, 1.18-3.94; P = .02) but not Argentina (relative risk, 1. 09; 95% confidence interval, 0.70-1.68; P = .70). Conclusions: This study further supports the role of infectious agents in modulating asthma and allergy development.

Original languageEnglish
Pages (from-to)350-355
Number of pages6
JournalAnnals of Allergy, Asthma and Immunology
Volume92
Issue number3
StatePublished - Mar 2004

Fingerprint

BCG Vaccine
Hypersensitivity
Parturition
Asthma
Argentina
Thailand
Confidence Intervals
Turkey
Proteins
Parents
Newborn Infant
Skin Tests
Allergens
Communicable Diseases
History

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy

Cite this

Townley, R. G., Barlan, I. B., Patino, C., Vichyanond, P., Minervini, M. C., Simasathien, T., ... Hopp, R. J. (2004). The effect of BCG vaccine at birth on the development of atopy or allergic disease in young children. Annals of Allergy, Asthma and Immunology, 92(3), 350-355.

The effect of BCG vaccine at birth on the development of atopy or allergic disease in young children. / Townley, R. G.; Barlan, I. B.; Patino, C.; Vichyanond, P.; Minervini, M. C.; Simasathien, T.; Nettagul, R.; Bahceciler, N. N.; Basdemir, D.; Akkoc, T.; Pongprueksa, S.; Hopp, R. J.

In: Annals of Allergy, Asthma and Immunology, Vol. 92, No. 3, 03.2004, p. 350-355.

Research output: Contribution to journalArticle

Townley, RG, Barlan, IB, Patino, C, Vichyanond, P, Minervini, MC, Simasathien, T, Nettagul, R, Bahceciler, NN, Basdemir, D, Akkoc, T, Pongprueksa, S & Hopp, RJ 2004, 'The effect of BCG vaccine at birth on the development of atopy or allergic disease in young children', Annals of Allergy, Asthma and Immunology, vol. 92, no. 3, pp. 350-355.
Townley RG, Barlan IB, Patino C, Vichyanond P, Minervini MC, Simasathien T et al. The effect of BCG vaccine at birth on the development of atopy or allergic disease in young children. Annals of Allergy, Asthma and Immunology. 2004 Mar;92(3):350-355.
Townley, R. G. ; Barlan, I. B. ; Patino, C. ; Vichyanond, P. ; Minervini, M. C. ; Simasathien, T. ; Nettagul, R. ; Bahceciler, N. N. ; Basdemir, D. ; Akkoc, T. ; Pongprueksa, S. ; Hopp, R. J. / The effect of BCG vaccine at birth on the development of atopy or allergic disease in young children. In: Annals of Allergy, Asthma and Immunology. 2004 ; Vol. 92, No. 3. pp. 350-355.
@article{1641f3387e944e42b13c4d48e7c08cee,
title = "The effect of BCG vaccine at birth on the development of atopy or allergic disease in young children",
abstract = "Background: Exposure to infectious diseases may reduce the development of asthma or allergy. In particular, the role of the BCG vaccine in modulating asthma or allergy has been a source of speculation. Objective: To study newborns from 3 international sites to evaluate the prospective effect of BCG vaccine on allergic diseases or atopic development. Methods: Infants were enrolled from newborn and well-infant clinics in Thailand, Argentina, and Turkey. The standard BCG vaccine for each country was given at birth. Parents who consented to have their infant included in the protocol completed an allergy family questionnaire. Infants underwent a standard purified protein derivative (PPD) test at 9 to 12 months of age, and the reaction size was measured. At the age of 2 years, the children returned to be studied. Allergy skin tests to common allergens appropriate to location and age were performed, and the parents completed the International Study of Allergy and Asthma in Childhood questionnaire. The PPD reaction size was compared with the presence of atopy and allergy questionnaire responses. Results: A total of 1,704 infants were studied. Statistical significance was found between a negative PPD response vs any positive PPD response and the risk of having an allergic history at the age of 2 years in Turkey (relative risk, 2.11; 95{\%} confidence interval, 1.25-3.55; P = .005) and Thailand (relative risk, 2.16; 95{\%} confidence interval, 1.18-3.94; P = .02) but not Argentina (relative risk, 1. 09; 95{\%} confidence interval, 0.70-1.68; P = .70). Conclusions: This study further supports the role of infectious agents in modulating asthma and allergy development.",
author = "Townley, {R. G.} and Barlan, {I. B.} and C. Patino and P. Vichyanond and Minervini, {M. C.} and T. Simasathien and R. Nettagul and Bahceciler, {N. N.} and D. Basdemir and T. Akkoc and S. Pongprueksa and Hopp, {R. J.}",
year = "2004",
month = "3",
language = "English",
volume = "92",
pages = "350--355",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "3",

}

TY - JOUR

T1 - The effect of BCG vaccine at birth on the development of atopy or allergic disease in young children

AU - Townley, R. G.

AU - Barlan, I. B.

AU - Patino, C.

AU - Vichyanond, P.

AU - Minervini, M. C.

AU - Simasathien, T.

AU - Nettagul, R.

AU - Bahceciler, N. N.

AU - Basdemir, D.

AU - Akkoc, T.

AU - Pongprueksa, S.

AU - Hopp, R. J.

PY - 2004/3

Y1 - 2004/3

N2 - Background: Exposure to infectious diseases may reduce the development of asthma or allergy. In particular, the role of the BCG vaccine in modulating asthma or allergy has been a source of speculation. Objective: To study newborns from 3 international sites to evaluate the prospective effect of BCG vaccine on allergic diseases or atopic development. Methods: Infants were enrolled from newborn and well-infant clinics in Thailand, Argentina, and Turkey. The standard BCG vaccine for each country was given at birth. Parents who consented to have their infant included in the protocol completed an allergy family questionnaire. Infants underwent a standard purified protein derivative (PPD) test at 9 to 12 months of age, and the reaction size was measured. At the age of 2 years, the children returned to be studied. Allergy skin tests to common allergens appropriate to location and age were performed, and the parents completed the International Study of Allergy and Asthma in Childhood questionnaire. The PPD reaction size was compared with the presence of atopy and allergy questionnaire responses. Results: A total of 1,704 infants were studied. Statistical significance was found between a negative PPD response vs any positive PPD response and the risk of having an allergic history at the age of 2 years in Turkey (relative risk, 2.11; 95% confidence interval, 1.25-3.55; P = .005) and Thailand (relative risk, 2.16; 95% confidence interval, 1.18-3.94; P = .02) but not Argentina (relative risk, 1. 09; 95% confidence interval, 0.70-1.68; P = .70). Conclusions: This study further supports the role of infectious agents in modulating asthma and allergy development.

AB - Background: Exposure to infectious diseases may reduce the development of asthma or allergy. In particular, the role of the BCG vaccine in modulating asthma or allergy has been a source of speculation. Objective: To study newborns from 3 international sites to evaluate the prospective effect of BCG vaccine on allergic diseases or atopic development. Methods: Infants were enrolled from newborn and well-infant clinics in Thailand, Argentina, and Turkey. The standard BCG vaccine for each country was given at birth. Parents who consented to have their infant included in the protocol completed an allergy family questionnaire. Infants underwent a standard purified protein derivative (PPD) test at 9 to 12 months of age, and the reaction size was measured. At the age of 2 years, the children returned to be studied. Allergy skin tests to common allergens appropriate to location and age were performed, and the parents completed the International Study of Allergy and Asthma in Childhood questionnaire. The PPD reaction size was compared with the presence of atopy and allergy questionnaire responses. Results: A total of 1,704 infants were studied. Statistical significance was found between a negative PPD response vs any positive PPD response and the risk of having an allergic history at the age of 2 years in Turkey (relative risk, 2.11; 95% confidence interval, 1.25-3.55; P = .005) and Thailand (relative risk, 2.16; 95% confidence interval, 1.18-3.94; P = .02) but not Argentina (relative risk, 1. 09; 95% confidence interval, 0.70-1.68; P = .70). Conclusions: This study further supports the role of infectious agents in modulating asthma and allergy development.

UR - http://www.scopus.com/inward/record.url?scp=12144287976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144287976&partnerID=8YFLogxK

M3 - Article

VL - 92

SP - 350

EP - 355

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 3

ER -